

TRANSRENAL VACCINE LIPOSOME

Publication number: JP8183742 (A)
Publication date: 1996-07-16
Inventor(s): TSUCHIYA HARUTSUGU; ARAMAKI YUKIHIKO; KIKUCHI HIROSHI; YANAI KIYOTO;
FUJII YOSHIMINE +
Applicant(s): DAIICHI SEIYAKU CO +
Classification:
- international: A61K39/385; A61K9/127; A61K39/385; A61K9/127; (IPC1-7): A61K39/385;
A61K9/127
- European:
Application number: JP19940339627 19941228
Priority number(s): JP19940339627 19941228

Abstract of JP 8183742 (A)


PURPOSE: To provide a nasal vaccine which contains the liposome in which the antigen is bonded through a lipid for bonding an antigen to its membrane surface. CONSTITUTION: The antigen is bonded to the lipid on the surface of liposome membrane (such as N-hydroxysuccinimide palmitic acid ester) using the amino or thiol group in the antigen molecule which is capable of producing the antibody. The liposome is constituted additionally using phospholipid, adjuvant, cholesterol, surfactant, antioxidant and the like. The proportion of the lipid bondable to the antigen accounts to 0.5-20 mole% based on the total lipid constituting the liposome membrane. This antigen in a liposome suspension is sprayed in the nasal cavity to increase the antibody value to prevent infection.

Data supplied from the *espacenet* database — Worldwide

LIPOSOME PHARMACEUTICAL PREPARATION

Publication number: JP6183954 (A)
Publication date: 1994-07-05
Inventor(s): KATOU YASUKI; HOSOKAWA TOSHIHITO; HAYAKAWA EIJI +
Applicant(s): KYOWA HAKKO KOGYO KK +
Classification:
- international: **A61K47/12; A61K47/24; A61K9/127; A61K47/12; A61K47/24; A61K9/127;**
(IPC1-7): A61K47/12; A61K47/24; A61K9/127
- European:
Application number: JP19920344115 19921224
Priority number(s): JP19920344115 19921224

Abstract of JP 6183954 (A)
PURPOSE: To obtain the subject pharmaceutical preparation, composed of a medicine, a phospholipid and a fatty acid salt, capable of suppressing the distribution into a reticuloendothelial system and prolonging the retention time of the medicine in blood, excellent in persistence of pharmacodynamic effects and useful as a parenteral injection, etc.
CONSTITUTION: This pharmaceutical preparation is composed of (A) a medicine such as cisplatin, (B) a phospholipid such as phosphatidylcholine and (C) a fatty acid salt such as sodium caprylate in an amount of preferably 0.1-50wt % [based on the ingredient (B)].



Data supplied from the *espacenet* database — Worldwide